论文部分内容阅读
自从1987年美国开发出第一种调节血脂新药——洛伐他汀以来,国外已先后开发出一系列他汀类调脂药,包括辛伐他汀、普伐他汀、阿伐他汀、氟伐他汀和新上市的西伐他汀等等。有人将它的发现与青霉素相提并论,有的学者干脆提出“调脂的年代,他汀的革命”。正当大家对他汀类调脂药寄予厚望时,2001年8月,发生了使用西立伐他汀造成横纹肌溶解,导致52人死亡的事件。西立伐他汀(商品名拜斯亭)的生产厂家拜耳公司与美国食品药品管理局(FDA)取得一致后,主动将拜斯亭撤出了美国市场。这一来,使众多的医生和患者更加关注他汀类药物的安全性问题。用,还是不用?人们感到很疑惑。为了让人们对他汀类药物有全面的认识,消除心中的疑问,我们特推出本期“专家评药”。
Since the United States developed the first lipid-lowering drug lovastatin in 1987, a series of statin lipid-lowering drugs have been developed abroad, including simvastatin, pravastatin, atorvastatin, fluvastatin and fluoxetine Listed simvastatin and so on. Some people have compared its findings with penicillin, and some scholars simply put forward the “fat age, the revolution of statins.” Just as everyone had great hopes for statin lipid-lowering drugs, in August 2001, the use of cerivastatin caused rhabdomyolysis, resulting in 52 deaths. After the agreement between Bayer AG and the US Food and Drug Administration (FDA), the manufacturer of cerivastatin (trade name Baisiting) took the initiative to withdraw Baisiting from the U.S. market. This led many doctors and patients to pay more attention to the safety of statins. Use, or not? People are very puzzled. In order to give people a full understanding of statins, to eliminate the hearts of doubt, we launched this issue of “expert evaluation of drugs.”